Bottle of Souvenaid liquid and Souvenaid powder tin

Souvenaid®

Souvenaid® nutritionally supports memory function in the early stage of Alzheimer's disease, including mild cognitive impairment when taken daily over 3 years.1

 

Individual results may vary.1

Get a sample
 

 

What is Souvenaid®?

  • Souvenaid® is a medical nutrition drink that is specially formulated to support memory function in the early stages of Alzheimer’s disease.1
  • Powered by a unique combination of nutrients known as Fortasyn® Connect, formulated to nutritionally support the growth of brain connections.1
  •  Available in 125ml ready-to-drink liquid or 360g powder
  • 5 delicious flavours available
  • Backed by 20 years of evidence based research*
  • Souvenaid® is proven to slow memory and cognitive decline by an average of 60% in mild cognitive impairment due to Alzheimer's disease when taken daily for 3 years.2-3 Individual results may vary.2-3

 

View all products

 

 

Need help finding information?

Living with early Alzheimer’s disease including mild cognitive impairment brings up a lot of questions. Find out how and where to buy Souvenaid® or request a sample. Ask your healthcare professional for a recommendation before you buy or order.

A woman sitting in front of a laptop and using her phone

How to buy Souvenaid®

Souvenaid® Liquid or Powder is available at NutriciaStore, pharmacies across Australia and through medical distributors. Order over the phone, buy online or instore.

Where to buy
Woman in a kitchen holding an open bottle of Souvenaid

How can I try Souvenaid®?

Have you been recommended Souvenaid® by your healthcare professional?  Fill out the form to get a free sample delivered to your door. It’s a great way to see if Souvenaid® is a good match for you.

Get a sample
Senior man watering plants in a garden

I want to learn more about Souvenaid®

Explore our articles about Souvenaid® to find out how it supports memory function in early Alzheimer's disease including mild cognitive impairment (MCI).

Read articles

Caring for someone who is living with early Alzheimer’s disease including mild cognitive impairment brings up a lot of questions. Find out how and where to buy Souvenaid® or request a sample. Ask their healthcare professional for a recommendation before you buy or order.

Man and woman sitting on couch using their laptop

How to buy Souvenaid®

Souvenaid® Liquid or Powder is available at NutriciaStore, pharmacies across Australia and through medical distributors. Order over the phone, buy online or instore.

 

Where to buy
Man and woman sitting a table drinking souvenaid

How can we try Souvenaid®?

Has your loved one been recommended Souvenaid® by their healthcare professional?  Fill out the form to get a free sample delivered to their door. It's a great way to see if Souvenaid® is a good match for them.

Get a free sample
Senior couple embracing

Want to learn more about Souvenaid®?

Explore our articles about Souvenaid® to find out how it supports memory function in early Alzheimer's disease including mild cognitive impairment (MCI).

Read articles

Hear our real-life success stories

Bill’s story is truly inspiring. Learn about the lifestyle changes he’s made since his diagnosis. To see what other patients and carers think about Souvenaid® visit our reviews page.

#Incentive was provided for this testimonial.

 

 

 

 

A word from Gerald Quigley, Community Pharmacist for over 50 years

Learn more about Gerald Quigley
Senior couple looking out of a window

What is Alzheimer’s disease?

Alzheimer’s is a progressive, degenerative brain disease and the most common form of dementia.5 

 

Early symptoms include changes in memory or thinking such as missing appointments or losing things more often. 

Learn more

What can I expect from Souvenaid?

Illustration of a brain
Supports memory function in early Alzheimer's disease when taken daily for at least 6 months.1-3,6
Illustration of a microscope
Backed by 20 years of evidence-based research1-3,6*
Illustration of a neuron
Supported by an ongoing research program1-3,6

Souvenaid® is powered by Fortasyn® Connect, a unique combination of nutrients formulated to support memory function in early Alzheimer’s disease.4 Explore it's potential in our comprehensive articles. 

 

Explore articles

 

 

grandma clapping hands with grandaugher

What do our customers think of Souvenaid®?

Read testimonials from real Souvenaid® customers, carers and family as they navigate early Alzheimer's disease including mild cognitive impairment.

Read testimonials

 

 

Souvenaid® is a Food for Special Medical Purposes as classified by Food Standards Australia and New Zealand (FSANZ) as Standard 2.9.5. Souvenaid® is prescribed by a treating healthcare professional for the dietary management of early Alzheimer’s Disease/Mild Cognitive Impairment. Souvenaid® does not cure or alleviate Alzheimer’s disease. 

 

The information on this page is not intended to be a substitute for medical advice. Always seek medical advice from a healthcare professional.

*Based on a study published in 2021. Individual results may vary.

 

1 - Soininen H, et al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimer’s Dement. 2021;17(1):1-12.

 

2 - Scheltens P, et al. Efficacy of a medical food in mild Alzheimer’s Disease: A randomized controlled trial. Alzheimer’s Dement. 2010; 6:1-10.

 

3 - Scheltens P, et al. Efficacy of Souvenaid® in mild Alzheimer’s Disease: Results from a randomized controlled trial. J. Alzheimer’s Dis. 2012; 31:225-36.

 

4 - Sijben JWC, et al. A multi nutrient concept to enhance synapse formation and function: science behind a medical food for Alzheimer’s disease. OCL. 2011;18:267-70.

 

5 - Dementia Australia. Alzheimer’s Disease. Everything you need to know [Internet]. 2024 [cited 2025 Feb 6]. Available at: https://www.dementia.org.au/about-dementia/alzheimers-disease-everything-you-need-know   

 

6 - Shah RC, et al. The S-Connect study: results from a randomized, controlled trial of Souvenaid® in mild-to-moderate Alzheimer’s disease. Alzheimer’s Res Ther 2013;5(6):59.

x